TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
This study is testing a combination of standard chemotherapy, a blood-vessel blocking medication, and an immunotherapy drug to see if it helps patients with advanced lung cancer live longer and healthier lives. It focuses specifically on people who have never smoked or who have certain genetic changes in their tumors.
You may be able to join if you have stage 4 non-squamous non-small cell lung cancer, have either specific genetic mutations or have smoked fewer than 100 cigarettes in your lifetime, and meet specific prior treatment guidelines. Certain health conditions, such as recent severe bleeding, untreated large brain tumors, or major heart issues, will prevent you from participating.
Participants will receive a combination of medications designed to fight lung cancer, including chemotherapy, targeted treatments, and potentially immunotherapy. Your health and tumor size will be closely monitored throughout the process using imaging scans like CT scans or MRIs.
The study currently takes place in Philadelphia, Pennsylvania, in the United States. Please note that this study is currently active but not recruiting new participants.
- 1Tests a combination of chemotherapy, blood-vessel treatments, and immunotherapy for advanced lung cancer.
- 2Designed for people with specific genetic mutations or those who have never smoked.
- 3The study is currently active but not accepting new participants.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.